期刊文献+

苯乙醇胺类化合物的合成及其抗哮喘活性研究 被引量:2

Synthesis and anti-asthma activities of phenylethanolamine derivatives
原文传递
导出
摘要 目的设计合成2-胺基-1-苯基乙醇类化合物并研究其抗哮喘活性。方法以取代苯乙酮为原料,经α-溴代、胺解、还原、成盐等反应合成目标化合物,采用离体豚鼠气管条法和β2-肾上腺素受体激动剂钙流筛选模型测定目标化合物的药理活性。结果设计并合成了15个苯乙醇胺类化合物,其中12个化合物是未见文献报道的新化合物,其结构均经过1H-NMR及MS谱确证。结论所合成的化合物初步证明为2β-肾上腺素受体激动剂,具有不同程度的支气管舒张作用,其中化合物1a^1d显示出较好的活性,值得进一步深入研究。 Aim To design and synthesize 2-amino-l-phenylethanol derivatives and to evaluate their anti-asthma activities. Methods The target compounds were synthesized from substituted acetophenones via a-bromination, amination, reduction and salt-formation. And their effects on guinea-pig tracheal smooth muscle and β2-adrenoceptor were determined. Results Fifteen compounds were synthesized and twelve compounds were first reported. All the structures were confirmed by ^1H-NMR and MS. Conclusion Preliminary pharmacological studies revealed that the novel derivatives were β2-adrenoceptor agonists possessing relaxing activities on the contracting bronchial smooth muscle of guinea-pigs induced by histamine. Among them,la-ld exhibited high activities and were worthy of further investigation.
出处 《中国药物化学杂志》 CAS CSCD 2009年第2期94-98,共5页 Chinese Journal of Medicinal Chemistry
基金 国家高技术研究发展计划项目(863项目 2002AA233031 2005AA233030)
关键词 2-胺基-1-苯基乙醇类化合物 合成 支气管扩张活性 β2-肾上腺素受体激动剂 2-amino- 1 -phenylethanol derivatives synthesis bronchodilating activity β2-aderenoceptor agonists
  • 相关文献

参考文献2

二级参考文献41

  • 1Lai CK,Chest,1995年,108卷,1期,36页
  • 2An S, Bleu T, Zheng Y. Transduction of intracellular calcium signals through G protein-mediated activation of phospholipase C by recombinant sphingosine 1-phosphate receptors. Mol Pharmacol 1999; 55: 787-94.
  • 3Kest B, Lee CE, McLemore GL, Inturrisi CE, An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Res Bull 1996; 39: 185-8.
  • 4Quock RM, Burkey TH, Varga E, Hosohata Y, Hosohata K, Cowell SM, et al. The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy. Pharmacol Rev 1999; 51: 503-32.
  • 5Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F,Makriyannis A, et al. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol 1999; 126: 665-72.
  • 6Raport C J, Gosling J, Schweickart VL, Gray PW,Charo IF. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem 1996; 271: 17161-6.
  • 7Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, Idzan SR, et al. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4, Biochem Pharmacol 2006; 72: 588-96.
  • 8Cai YC, Ma L, Fan GH, Zhao J, Jiang LZ, Pei G. Activation of N-methyl-D-aspartate receptor attenuates acute responsiveness of delta-opioid receptors. Mol Pharmacol 1997; 51: 583-7.
  • 9Holmberg CI, Kukkonen JP, Bischoff A, Nasman J, Courtney MJ, Michel MC, et al. Alpha2B-adrenoceptors couple to Ca^2+ increase in both endogenous and recombinant expression systems. Eur J Pharmacol 1998; 363: 65-74.
  • 10George SR, O'Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002; 1: 808-20.

共引文献12

同被引文献48

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部